Paris, France and Cambridge, MA, USA – September 19, 2016
Enterome Bioscience SA (“Enterome”), a pioneer in the development of pharmaceuticals and diagnostics based on the gut microbiome, is pleased to announce that it has appointed Christophe Bonny, Ph.D. as Chief Scientific Officer (CSO). Dr. Bonny, will be responsible for developing and advancing Enterome’s R&D strategy focused on the identification of novel targets derived from the microbiome, and the development of molecules secreted by the gut microbiome that mediate interactions with the host – and not mixtures of bacterial strains – as potential new therapeutics.
Dr. Bonny joins Enterome with 20 years’ of medical research and industry experience with a strong background in drug discovery and pre-clinical development in the areas of inflammatory diseases and oncology. He was previously CSO at Bicycle Therapeutics in the UK and before that he worked at Switzerland-based Xigen where he served as CSO and President. Prior to Xigen, Dr. Bonny was Head of Research of the Medical Genetics Unit at the University Hospital of Lausanne, Switzerland. He obtained a Ph.D. in molecular biology from the University of Neuchâtel, Switzerland, and completed a business and entrepreneurship program at Babson College, US. Dr. Bonny is an author on over 100 scientific publications and is an inventor on multiple patents.
“Enterome has an exceptional opportunity to become a leading company developing innovative drugs and diagnostics based on its unrivalled understanding of the microbiome. In just a short time, Enterome has shown the power of its technology and is advancing its lead product, EB8018, which acts on a novel target in Crohn’s Disease. I am excited to join the Company at a time of significant momentum and I look forward to working to further develop and advance Enterome’s pipeline based on its world-class technologies and capabilities,” said Christophe Bonny, Ph.D.
“At Enterome, we are taking a radically different approach from other microbiome companies to pin down well-defined novel targets and develop small molecules and diagnostic products based on our technology platform. We are very pleased to welcome Dr. Bonny to Enterome and l am sure he will make an important contribution as we look to build a pipeline of novel therapeutic products based on our ‘drugs from bugs’ approach,” said Pierre Belichard, CEO of Enterome. “Enterome is at an important inflexion point as we look to leverage our technology, knowledge and industry partnerships to become one of the leading microbiome companies globally.”